NCT00542178View on ClinicalTrials.gov

Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

3,472

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Diabetic Retinopathy
Interventions
DRUG

Hypoglycemic Agents

Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%

DRUG

Standard glycemia control

A strategy of glycemia drugs for HbA1c 7% - 7.9%

DRUG

Intensive BP treatment

A strategy of multiple BP agents to reduce SBP less than 120 mm Hg

DRUG

Standard BP control

A strategy of BP drugs for SBP less than 140 mm Hg

DRUG

Fenofibrate

Blinded fenofibrate

DRUG

Simvastatin

Simvastatin 20-40 mg/d

DRUG

Placebo

Placebo

Trial Locations (7)

10032

Columbia University, New York

27157

Wake Forest University Health Sciences, Winston-Salem

55404

The Berman Center for Clinical Research, Minneapolis

98109

University of Washington, Seattle

44106-4951

Case Western Reserve University, Cleveland

38104-2193

Veterans Affairs, Memphis

L8L 2X2

McMaster University, Hamilton

All Listed Sponsors
collaborator

National Eye Institute (NEI)

NIH

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00542178 - Evaluating How the Treatments in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Affect Diabetic Retinopathy (The ACCORD Eye Study) | Biotech Hunter | Biotech Hunter